Results 221 to 230 of about 111,074 (325)

Proteomic and Allergenomic Profiling of Banana (<i>Musa</i> spp.): Identification of Potential Novel Allergens in Thai Adult Banana Allergy Cohort. [PDF]

open access: yesJ Asthma Allergy
Sangsuwan P   +10 more
europepmc   +1 more source

Drug Allergy Risk Stratification in Children With Immediate or Delayed Urticaria During Antibiotic Treatment

open access: yes
Clinical &Experimental Allergy, EarlyView.
Francesca Mori   +8 more
wiley   +1 more source

A retrospective audit of the real‐world safety and effectiveness profile of eptinezumab for treatment‐resistant chronic migraine in Australia

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To describe the real‐world safety, tolerability, and effectiveness of eptinezumab for chronic migraine prevention in Australia. Background Eptinezumab is a relatively new medication for treatment‐resistant chronic migraine prevention.
Lakshini Gunasekera   +7 more
wiley   +1 more source

Two Cases of Anaphylaxis After Laminaria Insertion [PDF]

open access: bronze, 2003
Sang Hoon Kim   +6 more
openalex   +1 more source

You Can’t Hold Their Hand the Whole Time: A Qualitative Study of Parents’ Experiences of Adolescents With Food Allergy

open access: yesJournal of Advanced Nursing, EarlyView.
ABSTRACT Aims To explore parents’ experiences of parenting adolescents with food allergies. Design An interpretive descriptive qualitative study. Methods Semi‐structured interviews were conducted between November 2023 and March 2024 with 11 parents of adolescents with food allergies aged 12–16 years, 8 mothers and 3 fathers. Reflexive thematic analysis
Meg O’ Sullivan   +4 more
wiley   +1 more source

Early Walnut Powder Introduction for Prevention of Walnut Sensitisation in High‐Risk Infants With Eczema: An Open‐Label, Randomised, Non‐Inferiority Trial

open access: yes
Clinical &Experimental Allergy, EarlyView.
Sayaka Hamaguchi   +16 more
wiley   +1 more source

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy